分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy

Fan Xiao-Yan, Guo Lei, Chen Lei-Ning, Yin Shen, Wen Jiarong, Li Sen, Ma Jun-Yu, Jing Tao, Jiang Man-Xi, Sun Xiao-Hong, Chen Meilan, Wang Feng, Wang Zhen-Bo, Zhang Chang-Fa, Wang Xing-Hua, Ge Zhao-Jia

Journal:Nature Biomedical Engineering

IF:29.23

DOI:10.1038/s41551-022-00881-7

PMID:35437313

Published:2022-04-18

research field:氧化应激生物学免疫学炎症研究血液学信号转导

Abstract

Mitochondrial replacement therapy (MRT) has been used to prevent maternal transmission of disease-causing mutations in mitochondrial DNA (mtDNA). However, because MRT requires nuclear transfer, it carries the risk of mtDNA carryover and hence of the reversion of mtDNA to pathogenic levels owing to selective replication and genetic drift. Here we show in HeLa cells, mouse embryos and human embryos that mtDNA heteroplasmy can be reduced by pre-labelling the mitochondrial outer membrane of a donor zygote via microinjection with an mRNA coding for a transmembrane peptide fused to an autophagy receptor, to induce the degradation of the labelled mitochondria via forced mitophagy. Forced mitophagy reduced mtDNA carryover in newly reconstructed embryos after MRT, and had negligible effects on the growth curve, reproduction, exercise capacity and other behavioural characteristics of the offspring mice. The induction of forced mitophagy to degrade undesired donor mtDNA may increase the clinical feasibility of MRT and could be extended to other nuclear transfer techniques.

本文使用的Yeasen产品

购物车
客服
转染试用